Medicine
Methotrexate Toxicity and Leucovorin Rescue Protocols
Quick fact
Leucovorin is not a vitamin supplement; it's a drug that bypasses a blocked metabolic step. When given at the right time after methotrexate, it can prevent life-threatening bone marrow suppression.
Why this is interesting
You've heard of chemotherapy, but what if I told you that a key cancer drug can be deadly to healthy cells unless you 'rescue' them with a vitamin-like pill? How do doctors manage to use such a double-edged sword?
Read the full explanation
Understanding Methotrexate Toxicity and Leucovorin Rescue Protocols
Methotrexate works by blocking an enzyme called dihydrofolate reductase (DHFR). This enzyme normally converts dietary folate into its active form, which is essential for making DNA building blocks (thymidylate) and certain amino acids. By inhibiting DHFR, methotrexate stops fast-dividing cells—like cancer cells—from multiplying. But it also affects healthy fast-dividing cells, such as those in bone marrow and the lining of the mouth and intestines. This causes side effects like low blood counts and mouth sores. Leucovorin is a form of folate that does not need DHFR to become active. When given after methotrexate, it enters cells and provides the missing active folate, allowing them to resume DNA synthesis. The trick is timing: if leucovorin is given too early, it can 'rescue' cancer cells as well; if given too late or in insufficient doses, it fails to protect healthy cells. Thus, protocols specify the exact dose and timing based on methotrexate blood levels.
A deeper explanation
The selective rescue relies on a pharmacokinetic principle. Methotrexate is typically administered as a high-dose infusion over 24 hours. During this time, cancer cells are exposed to a lethal concentration. After the infusion, the drug is eliminated by the kidneys, but healthy tissues may still have accumulated methotrexate. Leucovorin is then started 24 hours after the infusion begins. Its administration is guided by measuring methotrexate levels in the blood: if the level is high, the leucovorin dose is increased and given more frequently. This 'rescue' is possible because leucovorin is actively converted to active folate cofactors, and cancer cells—often deficient in the enzyme that converts leucovorin (FPGS)—take it up less efficiently than healthy cells. Therefore, healthy cells are replenished, while cancer cells remain starved of folate and die. Understanding this protocol is crucial because errors in timing or dosing can lead to fatal toxicity. The same principle underlies the use of methotrexate in autoimmune diseases, where lower doses are used and leucovorin is given as a 'washout' to reduce side effects.